keyword
MENU ▼
Read by QxMD icon Read
search

Ovarian hyperstimulation syndrome

keyword
https://www.readbyqxmd.com/read/28514122/-is-anti-thrombotic-prophylaxis-warranted-in-fertility-and-in-vitro-fertilization-treatments
#1
REVIEW
Enav Yefet, Amir Weiss
INTRODUCTION: Assisted reproductive technology (ART) treatments are potential risk factors for thromboembolism (TE) due to excessive estrogen levels. Recently, several studies have shed new light on this matter. AIMS: To review the literature to assess the risk for TE during ART and to establish guidelines regarding thrombophylaxis. METHODS: A search was conducted of PubMed, Medline, Cochrane and clinicaltrials.gov. The search terms were fertility, assisted reproductive technology, IVF, thromboembolism, thrombosis and anticoagulation...
July 2016: Harefuah
https://www.readbyqxmd.com/read/28506951/pharmacokinetic-pharmacodynamic-and-clinical-aspects-of-ovulation-induction-agents-a-review-of-the-literature
#2
Serkan Kahyaoğlu, Bülent Yılmaz, Ahmet Zeki Işık
Controlled ovarian hyperstimulation is a key step for successful outcomes of assisted reproductive technique cycle outcomes. Many medications are available, which are commonly useed solely or in combination to achieve multiple follicular development. Pharmacokinetic, pharmacodynamic, and clinical information of ovulation induction drugs deserve to be elucidated for every individual patient before commencing infertility treatment. New concepts and new treatment protocols are introduced as ovulation physiology is understood by infertility specialists...
March 15, 2017: Journal of the Turkish German Gynecological Association
https://www.readbyqxmd.com/read/28501428/management-of-ovarian-stimulation-for-ivf-narrative-review-of-evidence-provided-for-world-health-organization-guidance
#3
REVIEW
Cindy Farquhar, Jane Marjoribanks, Julie Brown, Bart C J M Fauser, Anne Lethaby, Selma Mourad, Robert Rebar, Marian Showell, Sheryl van der Poel
In this paper, a review of evidence provided to the World Health Organization (WHO) guideline development, who prepare global guidance on the management of ovarian stimulation for women undergoing IVF, is presented. The purpose of ovarian stimulation is to facilitate retrieval of multiple oocytes during a single IVF cycle. Availability of multiple oocytes compensates for inefficiencies in subsequent stages of the cycle, which include oocyte maturation, IVF, embryo culture, embryo transfer, and implantation...
April 26, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/28501361/intrauterine-insemination-with-gonadotropin-stimulation-or-in%C3%A2-vitro-fertilization-for-the-treatment-of-unexplained-subfertility-a-randomized-controlled-trial
#4
Anupa Nandi, Priya Bhide, Richard Hooper, Anil Gudi, Amit Shah, Khalid Khan, Roy Homburg
OBJECTIVE: To evaluate the best first line management option for the treatment of unexplained subfertility-controlled ovarian hyperstimulation (COH) with gonadotropins and IUI or IVF. DESIGN: Randomized controlled trial. SETTING: Single center trial in a tertiary referral unit. PATIENT(S): Couples with unexplained subfertility. INTERVENTION(S): Couples were randomized to receive either three cycles of IUI + COH or one cycle of IVF...
May 10, 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/28476487/a-randomized-controlled-trial-comparing-the-efficacy-and-safety-of-two-hmg-preparations-gaining-their-lh-bioactivity-from-different-hcg-sources
#5
Gillian Lockwood, Barbara Cometti, Jeanette Bogstad, Karin Erb, Christian De Geyter, Janos Urbancsek, Silvia Trevisan, Khaled Pocate-Cheriet, Dominique de Ziegler
In this prospective, controlled, randomized, multicentre, non-inferiority study, efficacy and safety of two HMG preparations (Menopur(®)- Ferring and Meriofert®- IBSA Institut Biochimique SA) for ovarian stimulation were compared (270 women undergoing IVF aged between 18 and 39 years; BMI 30 kg/m(2) or less; less than three prior completed assisted reproduction technique cycles). A standard long down-regulation with gonadotrophin-releasing hormone agonist protocol, with HCG triggering was used; primary end-point was total number of oocytes retrieved; attention was paid toovarian hyperstimulation syndrome (OHSS)...
April 20, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/28473127/long-term-breast-cancer-risk-following-ovarian-stimulation-in-young-egg-donors-a-call-for-follow-up-research-and-informed-consent
#6
Jennifer Schneider, Jennifer Lahl, Wendy Kramer
In the USA and other countries, oocyte donation is gaining increasing importance. Although sufficient data exist on procedure-associated short-term risks for oocyte donors, such as ovarian hyperstimulation syndrome, long-term follow-up studies of egg donors are lacking and their health risks are unknown. The lack of information may be misleadingly interpreted as lack of risk. Long-term hormone replacement therapy is recognized as a risk factor for breast cancer; the breast cancer risk of ovarian stimulation for egg donors is unknown but is a possibility...
May 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/28467768/gnrh-agonist-triggering-of-ovulation-replacing-hcg-a-30-year-old-revolution-in-ivf-practice-led-by-rambam-health-care-campus
#7
REVIEW
Shahar Kol, Ofer Fainaru
Final oocyte maturation is a crucial step in in vitro fertilization, traditionally achieved with a single bolus of human chorionic gonadotropin (hCG) given 36 hours before oocyte retrieval. This bolus exposes the patient to the risks of ovarian hyperstimulation syndrome (OHSS), particularly in the face of ovarian hyper-response to gonadotropins. Although multiple measures were developed to prevent OHSS, gonadotropin-releasing hormone (GnRH) agonist triggering is now globally recognized as the best approach to achieve this goal...
April 28, 2017: Rambam Maimonides Medical Journal
https://www.readbyqxmd.com/read/28462400/association-of-460c-t-and-405-g-c-polymorphisms-of-vascular-endothelial-growth-factor-gene-and-susceptibility-to-ovarian-hyperstimulation-syndrome
#8
Nasrin Ghasemi, Razieh Dehghani Firouzabadi, Shahnaz Ahmadi
BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is one of the most important complications of assisted reproduction treatment. Many substances are involved in the regulation of the vascular permeability, which have been concerned to cause OHSS. Vascular endothelial growth factor (VEGF) has emerged as one of the main angiogenic factors, which could be responsible for increased vascular permeability. OBJECTIVE: In this study the association of vascular endothelial growth factor -460C/T and +405 G/C polymorphisms and susceptibility to ovarian hyperstimulation syndrome was evaluated...
February 2017: International Journal of Reproductive Biomedicine (Yazd, Iran)
https://www.readbyqxmd.com/read/28461237/-ovarian-hyperstimulation-syndrome-after-stimulation-with-highly-purified-hmgfor-in-vitro-fertilization-observational-study-shoview
#9
P Barrière, D Dewailly, A Duhamel, V Gayet
OBJECTIVE: Data on the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in France are limited. METHODS: Prospective observational multicentric study (23 French centers of IVF) in a cohort of 421 women treated with highly purified hMG (HP-hMG) for the first or second cycle of IVF with or without ICSI. The primary objective was to assess the incidence of moderate to severe OHSS in this cohort. RESULTS: At inclusion, 172 patients (40...
May 2017: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/28459828/individual-luteolysis-pattern-after-gnrh-agonist-trigger-for-final-oocyte-maturation
#10
Barbara Lawrenz, Nicolas Garrido, Suzan Samir, Francisco Ruiz, Laura Melado, Human M Fatemi
Final oocyte maturation using GnRH-agonist trigger in a GnRH-antagonist protocol is increasingly common, as ovarian hyperstimulation syndrome is almost completely avoided. However, this approach might lead to reduced pregnancy rates due to severe luteolysis. This proof of concept study evaluated the extend of luteolysis by measuring progesterone levels 48 hours after oocyte retrieval in 51 patients, who received GnRH-agonist trigger for final oocyte maturation in a GnRH-antagonist protocol due to the risk of ovarian hyperstimulation syndrome...
2017: PloS One
https://www.readbyqxmd.com/read/28455751/national-trends-and-outcomes-of-autologous-in-vitro-fertilization-cycles-among-women-ages-40-years-and-older
#11
Heather Hipp, Sara Crawford, Jennifer F Kawwass, Sheree L Boulet, David A Grainger, Dmitry M Kissin, Denise Jamieson
PURPOSE: The purpose of the study was to describe trends in and investigate variables associated with clinical pregnancy and live birth in autologous in vitro fertilization (IVF) cycles among women ≥40 years. METHODS: We used autologous IVF cycle data from the National ART Surveillance System (NASS) for women ≥40 years at cycle start. We assessed trends in fresh and frozen cycles (n = 371,536) from 1996 to 2013. We reported perinatal outcomes and determined variables associated with clinical pregnancy and live birth in fresh cycles between 2007 and 2013...
April 28, 2017: Journal of Assisted Reproduction and Genetics
https://www.readbyqxmd.com/read/28446136/first-mutation-in-the-fshr-cytoplasmic-tail-identified-in-a-non-pregnant-woman-with-spontaneous-ovarian-hyperstimulation-syndrome
#12
Justine Hugon-Rodin, Charlotte Sonigo, Anne Gompel, Catherine Dodé, Michael Grynberg, Nadine Binart, Isabelle Beau
BACKGROUND: Spontaneous ovarian hyperstimulation syndrome (sOHSS) is a rare event occurring mostly during natural pregnancy. Among described etiologies, some activating mutations of FSH receptor (FSHR) have been identified. CASE PRESENTATION: We report hereby the case of a non-pregnant women with three episodes of sOHSS. Hormonal evaluation was normal and no pituitary adenoma was detected. However, genetic analysis identified a novel heterozygous FSHR mutation (c...
April 26, 2017: BMC Medical Genetics
https://www.readbyqxmd.com/read/28441461/sliding-scale-hcg-trigger-yields-equivalent-pregnancy-outcomes-and-reduces-ovarian-hyperstimulation-syndrome-analysis-of-10-427-ivf-icsi-cycles
#13
Vinay Gunnala, Alexis Melnick, Mohamad Irani, David Reichman, Glenn Schattman, Owen Davis, Zev Rosenwaks
OBJECTIVE: To evaluate pregnancy outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS) using a sliding scale hCG protocol to trigger oocyte maturity and establish a threshold level of serum b-hCG associated with optimal oocyte maturity. DESIGN: Retrospective cohort. SETTING: Academic medical center. PATIENTS: Fresh IVF cycles from 9/2004-12/2011. INTERVENTION: 10,427 fresh IVF-ICSI cycles met inclusion criteria...
2017: PloS One
https://www.readbyqxmd.com/read/28440715/gnrh-agonist-triggering-for-final-oocyte-maturation-in-gnrh-antagonist-ivf-cycles-induces-decreased-lh-pulse-rate-and-amplitude-in-early-luteal-phase-a-possible-luteolysis-mechanism
#14
Samer Tannus, Yechiel Burke, Christopher R McCartney, Shahar Kol
The use of GnRH agonist to trigger final oocyte maturation in GnRH-antagonist in vitro fertilization (IVF) cycles has been shown to significantly reduce or even eliminate the risk of ovarian hyperstimulation syndrome (OHSS) by inducing rapid luteolysis early in the luteal phase. The exact mechanism of this early luteolysis is still widely unknown. Since luteinizing hormone (LH) has a major role in corpus luteum support, we sought to explore the pattern of LH secretion early in the luteal phase. Ten high risk patients for developing OHSS and triggered with GnRH agonist were included...
April 25, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28440686/severe-ovarian-hyperstimulation-syndrome-after-combined-gnrh-agonist-and-low-dose-human-chorionic-gonadotropin-trigger-in-a-patient-with-a-single-kidney
#15
Nigel Pereira, Jovana P Lekovich, Isaac Kligman, Zev Rosenwaks
Ovarian hyperstimulation syndrome (OHSS) following gonadotropin-releasing hormone agonist (GnRH-a) trigger is rare. Here, we report a case of severe OHSS after combined GnRH-a and low-dose human chorionic gonadotropin (hCG) trigger in a patient with a single kidney. The patient is a 32-year-old women with a two-year history of infertility. The patient's history was significant for a single kidney, that is, she had donated a kidney to a family member three years ago. The patient underwent controlled ovarian stimulation (COS) for in vitro fertilization (IVF) and received a combined 2 mg GnRH-a and 1500 IU hCG ovulatory trigger...
April 25, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28437434/comparisons-of-gnrh-antagonist-protocol-versus-gnrh-agonist-long-protocol-in-patients-with-normal-ovarian-reserve-a-systematic-review-and-meta-analysis
#16
Ruolin Wang, Shouren Lin, Yong Wang, Weiping Qian, Liang Zhou
OBJECTIVE: To evaluate the effectiveness and safety of gonadotropin-releasing hormone antagonist (GnRH-ant) protocol and gonadotropin-releasing hormone agonist (GnRH-a) long protocol in patients with normal ovarian reserve. METHODS: We searched the PubMed (1992-2016), Cochrane Library (1999-2016), Web of Science (1950-2016), Chinese Biomedical Database (CBM, 1979-2016), and China National Knowledge Infrastructure (CNKI, 1994-2016). Any randomized controlled trials (RCTs) that compared GnRH-ant protocol and GnRH-a long protocol in patients with normal ovarian reserve were included, and data were extracted independently by two reviewers...
2017: PloS One
https://www.readbyqxmd.com/read/28423955/double-ovarian-stimulation-duostim-protocol-for-fertility-preservation-in-female-oncology-patients
#17
Nikolaos Tsampras, Della Gould, Cheryl T Fitzgerald
This article describes a revised ovarian stimulation protocol (DuoStim) for fertility preservation in female oncology patients which aims to maximise the number of gametes obtained with subsequent improvement in cumulative birth rate, without delaying cancer treatment. Ten patients diagnosed with malignancy between September 2014 and October 2015 were included. The patients were treated with the DuoStim protocol, undergoing two consecutive ovarian stimulation cycles and two oocyte retrievals. The primary outcome was the number of oocytes collected and vitrified during each oocyte retrieval and in total...
February 9, 2017: Human Fertility: Journal of the British Fertility Society
https://www.readbyqxmd.com/read/28422380/comparing-the-long-acting-and-short-acting-forms-of-gonadotropin-releasing-hormone-agonists-in-the-long-protocol-of-ivf-icsi-cycles-a-retrospective-study
#18
Liyan Duan, Shihua Bao, Kunming Li, Xiaoming Teng, Ling Hong, Xiaoyu Zhao
AIM: This study aimed to compare the efficacy of long- and short-acting gonadotropin-releasing hormone agonist on clinical outcomes of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) long protocol cycles. METHODS: In this retrospective study, 478 patients were enrolled from October 2012 to November 2014. The pituitary downregulation result, serum hormone levels, gonadotropin (Gn) dose during controlled ovarian hyperstimulation, and outcome of IVF/ICSI-embryo transfer were compared between the two groups...
April 19, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28416291/cumulative-live-birth-rate-after-gnrh-agonist-trigger-and-elective-cryopreservation-of-all-embryos-in-high-responders
#19
Veljko Vlaisavljević, Borut Kovačič, Jure Knez
Elective embryo cryopreservation after using gonadotrophin-releasing hormone (GnRH) antagonist protocols and GnRH agonist triggering is becoming an increasingly important part of medically assisted reproduction. We designed a single-centre retrospective study to assess the cumulative probability of achieving a live birth through consecutive transfers of vitrified-warmed blastocysts after elective embryo cryopreservation in high-responding patients. Hence, 123 women identified to be at high risk for developing ovarian hyperstimulation syndrome were included...
April 7, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/28403961/vascular-endothelial-growth-factor-antagonist-reduces-the-early-onset-and-the-severity-of-ovarian-hyperstimulation-syndrome
#20
S Jellad, A Haj Hassine, M Basly, A Mrabet, M Chibani, R Rachdi
BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of controlled ovarian stimulation (COH) during assisted reproductive technology (ART) protocols. This syndrome is a result of ovarian expression of vascular endothelial growth factor (VEGF), which increases vascular permeability. OBJECTIVES: To evaluate the efficiency of prophylactic and therapeutic use of cabergoline in women with higher risk of developing OHSS. MATERIALS AND METHODS: In this prospective randomized study, 146 women undergoing in vitro fertilization (IVF) cycles with GnRH agonist protocols with a higher risk of OHSS diagnosed during the HCG day administration (more than 18 follicles observed larger than 12mm in diameter during COH and/or estradiol levels of 3000-3500pg/ml, previous episodes of OHSS)...
January 2017: J Gynecol Obstet Hum Reprod
keyword
keyword
67327
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"